Literature DB >> 31350569

Targeting Vitamin D Deficiency to Limit Exacerbations in Respiratory Diseases: Utopia or Strategy With Potential?

Karen Maes1, Jef Serré2, Carolien Mathyssen2, Wim Janssens2, Ghislaine Gayan-Ramirez2.   

Abstract

Patients with respiratory diseases such as cystic fibrosis, chronic obstructive pulmonary disease, or asthma often experience an acute worsening of respiratory symptoms, termed exacerbations. Although the course of exacerbations is disease specific, they are mostly triggered by a respiratory infection. Exacerbations often require hospitalization and are an important cause of mortality. Treatments of exacerbations aim to minimize the negative impact and to prevent subsequent events. Despite many existing therapy options, many patients do not benefit from therapy and suffer from recurrent events. Vitamin D deficiency is a worldwide problem and is extremely prevalent in these patients. Vitamin D, known for its calcemic effects, also has immunomodulatory and anti-infectious actions and can therefore be a possible agent to treat or prevent exacerbations. This review will focus on vitamin D as a potential candidate to treat or prevent exacerbations in CF, COPD, and asthma.

Entities:  

Keywords:  Exacerbations; Lung; Vitamin D

Mesh:

Substances:

Year:  2019        PMID: 31350569     DOI: 10.1007/s00223-019-00591-4

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN: 0171-967X            Impact factor:   4.333


  9 in total

1.  Associations of VDR gene polymorphisms with risk of coal workers' pneumoconiosis in Chinese Han population.

Authors:  Xi Yang; Meiting Qin; Shanshan Cui; Qi Zhang
Journal:  Toxicol Res (Camb)       Date:  2020-06-17       Impact factor: 3.524

2.  Serum antioxidant vitamins and respiratory morbidity and mortality: a pooled analysis.

Authors:  Paivi M Salo; Angelico Mendy; Jesse Wilkerson; Samantha A Molsberry; Lydia Feinstein; Stephanie J London; Michael B Fessler; Peter S Thorne; Darryl C Zeldin
Journal:  Respir Res       Date:  2022-06-09

3.  Reply to Jakovac: About COVID-19 and vitamin D.

Authors:  Angelo Facchiano; Antonio Facchiano; Manuela Bartoli; Alberto Ricci; Francesco Facchiano
Journal:  Am J Physiol Endocrinol Metab       Date:  2020-06-01       Impact factor: 4.310

Review 4.  Current status of COVID-19 pandemic; characteristics, diagnosis, prevention, and treatment.

Authors:  Zary Nokhodian; Mohammad Mehdi Ranjbar; Parto Nasri; Nazila Kassaian; Parisa Shoaei; Bahareh Vakili; Soodabeh Rostami; Shahrzad Ahangarzadeh; Abbas Alibakhshi; Fatemeh Yarian; Shaghayegh Haghjooy Javanmard; Behrooz Ataei
Journal:  J Res Med Sci       Date:  2020-11-03       Impact factor: 1.852

Review 5.  Association Between Vitamin D and Novel SARS-CoV-2 Respiratory Dysfunction - A Scoping Review of Current Evidence and Its Implication for COVID-19 Pandemic.

Authors:  Aida Santaolalla; Kerri Beckmann; Joyce Kibaru; Debra Josephs; Mieke Van Hemelrijck; Sheeba Irshad
Journal:  Front Physiol       Date:  2020-11-26       Impact factor: 4.566

Review 6.  The health effects of vitamin D supplementation: evidence from human studies.

Authors:  Roger Bouillon; Despoina Manousaki; Cliff Rosen; Katerina Trajanoska; Fernando Rivadeneira; J Brent Richards
Journal:  Nat Rev Endocrinol       Date:  2021-11-23       Impact factor: 47.564

7.  A Meta-Analysis on Vitamin D Supplementation and Asthma Treatment.

Authors:  Meiqi Liu; Jun Wang; Xinrong Sun
Journal:  Front Nutr       Date:  2022-07-06

Review 8.  Recent advances in vitamin D implications in chronic respiratory diseases.

Authors:  Mellissa Gaudet; Maria Plesa; Andrea Mogas; Nour Jalaleddine; Qutayba Hamid; Saba Al Heialy
Journal:  Respir Res       Date:  2022-09-19

9.  Association of serum vitamin D levels with disease severity, systemic inflammation, prior lung function loss and exacerbations in a cohort of patients with chronic obstructive pulmonary disease (COPD).

Authors:  Ilka Jorde; Sabine Stegemann-Koniszewski; Kristin Papra; Sebastian Föllner; Anke Lux; Jens Schreiber; Eva Lücke
Journal:  J Thorac Dis       Date:  2021-06       Impact factor: 2.895

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.